3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
2
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
41
Recurrence
14
Prostatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Vomiting
1
Vascular Diseases
1
Paraproteinemias
1
Neoplasms
1
Neoplasm Metastasis
1
Nausea
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Plasma Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Hemostatic Disorders
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Blood Coagulation Disorders
1
Interventions
Dexamethasone
3
filanesib
2
Steroids
2
Injections, Subcutaneous
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Bortezomib
2
venetoclax
1
liposomal doxorubicin
1
Proteasome Inhibitors
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Plasma Cell
×
Calcium Dobesilate
×
Clear all
NCT01328236
2011-09-22
Bortezomib
Clinical Service, China
Phase 2
Unknown
20 enrolled